
    
      The study will focus on an innovative therapeutic strategy (DBS) and on an original
      objective, quality of life, which is considered to better reflect the impact of a therapeutic
      strategy. Moreover, the study will help to define the predictive biomarkers /biosignatures of
      response to STN DBS in OCD.
    
  